The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

X.c

Capillary leak syndrome (CLS)

Publications

Casadei Gardini A, Aquilina M, Oboldi D, Lucchesi A, Carloni S, Tenti E, Burgio MA, Amadori D, Frassineti GL

Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease.

BMC cancer. 2013;13:542

Spanos S, Vourliotaki I, Drossitis I, Tsoussis S

Cure of gemcitabine-induced systemic capillary leak syndrome without corticosteroids.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 2009;14(4):728-9

Dasanu CA

Gemcitabine: vascular toxicity and prothrombotic potential.

Expert opinion on drug safety. 2008;7(6):703-16

Baron D, Mayo A, Kluger Y

Gemcitabine-induced chronic systemic capillary leak syndrome: a life-threatening disease.

Clinical oncology (Royal College of Radiologists (Great Britain)). 2006;18(1):90-1

Biswas S, Nik S, Corrie PG

Severe gemcitabine-induced capillary-leak syndrome mimicking cardiac failure in a patient with advanced pancreatic cancer and high-risk cardiovascular disease.

Clinical oncology (Royal College of Radiologists (Great Britain)). 2004;16(8):577-9

De Pas T, Curigliano G, Franceschelli L, Catania C, Spaggiari L, de Braud F

Gemcitabine-induced systemic capillary leak syndrome.

Annals of oncology : official journal of the European Society for Medical Oncology. 2001;12(11):1651-2